“One of the many reasons we don’t have effective therapies for AD at the moment ... is that we don’t understand the beginnings of the disease,” Constanze Depp told BioWorld. Understanding those beginnings is likely to be a necessary prerequisite for truly turning the tide on Alzheimer’s disease (AD). “The brain is so bad at repairing itself, and once a neuron is lost, it will most likely not regenerate,” she elaborated. Now, Depp and her colleagues have reported on a contributor to those beginnings. Read More
Glucocorticoids are very effective immunosuppressive and anti-inflammatory drugs that cause dose-limiting toxicities in brain, liver and bone preventing their use mainly in chronic disorders. Researchers from Immunext Inc. recently reported results from the therapeutic evaluation of the nontoxic glucocorticoid INX-200 with anti-inflammatory efficacy in a once-per-month injection. Read More
Thryv Therapeutics Inc. has announced the closing of a $5 million convertible note investment, the proceeds of which will be used to accelerate development of its pipeline, including preclinical programs in anaplastic thyroid carcinoma and atrial fibrillation. Read More
CD38 is an enzyme with NAD-depleting and intracellular signaling activity expressed on the cell surface, in intracellular compartments and in mitochondria, and is linked to inflammatory and autoimmune diseases. Studies in CD38-deficient mice have revealed that these animals develop a type of collagen-induce arthritis (CIA) which suggests a link between CD38 and CIA pathogenesis. Read More
Two Vigil Neuroscience Inc. patents describe triggering receptor expressed on myeloid cells 2 (TREM2) agonists reported to be useful for the treatment of frontotemporal dementia, multiple sclerosis, rheumatoid arthritis, stroke, prion infections, Parkinson’s, Alzheimer’s and Nasu-Hakola diseases. Read More
Onquality Pharmaceuticals LLC has received FDA clearance of its IND application for OQL-051 for the prophylaxis of chemotherapy-induced diarrhea. Read More
Research at Biomea Fusion Inc. has led to the development of GTPase KRAS (G12C mutant) and (G12D mutant) inhibitors potentially useful for the treatment of cancer, autoimmune disease and inflammatory disorders. Read More
The pathogenesis of chronic pancreatitis (CP) is complex and involves interactions among different cell types, including pancreatic acinar, ductal and stellate cells (PSC). Researchers from Calcimedica Inc. and the University of Szeged set out to assess the pathogenic pathways in these cells as well as evaluate the potential of the novel calcium release-activated calcium channel protein 1 (Orai1) inhibitor CM-5480 as a potential treatment for CP. Read More
Defence Therapeutics Inc. has contracted Transbiotech Biotechnology Research and Transfer Center to test the potency of the company’s cellular anticancer ARM vaccine in animals with pre-established pancreatic tumors. Read More
Sanofi SA has prepared and tested isoxazolidines acting as receptor-interacting serine/threonine-protein kinase 1 (RIPK1; RIP-1) inhibitors. As such, they are reported to be useful for the treatment of Alzheimer’s disease, multiple sclerosis, amyotrophic lateral sclerosis and incontinentia pigmenti. Read More
Scientists from the Hospital for Sick Children Research Institute and collaborators have reported the application of a multispecific, multiaffinity antibody (Multabody, MB) platform derived from the human apoferritin protomer to enable the multimerization of antibody fragments against SARS-CoV-2. These MBs showed high potency to neutralize SARS-CoV-2 even at lower concentrations than their corresponding MAb counterparts. Read More
Insilico Medicine Inc. has reported the development of ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors described as useful for the treatment of cancer. Read More
Researchers at West China Hospital, Sichuan University have identified remimazolam derivatives reported to be useful for the treatment of sedation and as anesthetics. Read More
Researchers from Beijing Corregene Biotechnology Co. Ltd. presented preclinical data for CRTE7A2-01, a cell therapy candidate consisting of human T cells expressing T-cell receptors (TCRs) specific for HLA-A*02:01-restricted HPV16 E7 antigen. Read More
Tscan Therapeutics Inc. has received IND clearance by the FDA for TSC-200-A0201, a T-cell receptor (TCR) T-cell therapy targeting human papillomavirus 16 (HPV16), an oncogenic virus responsible for some cervical cancers and head and neck squamous cell carcinomas. Read More
.webp?t=1670008839 "Acute myeloid leukemia")
